A promising pipeline of updates for 2023 anticipated.
Potential 2023 updates:
- China / Hong Kong market entry; refer 14 Dec 22 ann/
"CEO Lange: ... We look forward to the first procedures being performed in this region in the coming months.."
“OncoSil is excited to be working with Hind Wing to distribute the OncoSilTM device in selected Chinese markets. We look forward to the first procedures being performed in this region in the coming months. OncoSil will continue to seek additional distribution agreements in regions where we do not have a physical presence to improve access to the OncoSil device for patients.” OncoSil’s CEO and Managing Director, Mr Nigel Lange said
- Germany market entry update; refer 28 Mar 22 ann/
"Fully-Funded Trial Approved In Germany To Increase Sales of OncoSilTM Device"OncoSil’s CEO and Managing Director, Mr Nigel Lange said:
“The G-BA agreeing to fully-fund a clinical trial in Germany, represents a very positive step forward in being able to better commercialise the OncoSilTM device in Germany. Favourable results from this trial will lead to public insurance reimbursement funding of the OncoSil device for all patients in Germany with Locally Advanced Pancreatic Cancer. In particular, the OncoSilTM device offers a promising treatment alternative in a disease of high unmet need. Revenue receipts from the provision of the OncoSil device in the clinical trial will also assist in accelerating revenue growth in Germany and eventually throughout Europe.” - also FDA update - UK update - Spain updates - Other countries market entry updates
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)